Natarajan Sethuraman - Mar 1, 2023 Form 4/A - Amendment Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Scientific Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
4/19/2023, 05:50 PM
Date Of Original Report
Mar 3, 2023
Previous filing
Sep 6, 2022
Next filing
Apr 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Award $0 +14.2K +8.82% $0.00 175K Mar 1, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Award $0 +21.5K $0.00 21.5K Mar 1, 2023 Common Stock 21.5K $12.25 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2 The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively.
F3 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.

Remarks:

This Form 4A is only to correct the reported amount to beneficial ownership of the Reporting Person.